Navigation Links
Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis

DURHAM, N.C.--(BUSINESS WIRE)--May 8, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced results of a Phase 2 dose-ranging clinical trial comparing epinastine nasal spray and placebo in patients with seasonal allergic rhinitis. For the primary endpoint of improvement in total nasal symptom score, dose-related effects were observed in the trial, with the higher dose (0.1%) achieving statistical superiority over placebo.

Christy L. Shaffer, Ph.D., Inspire's President and CEO, stated, "We were pleased that this trial identified an effective dose of epinastine in a nasal spray formulation, demonstrated evidence of acceptable tolerability and reported a low incidence of taste complaints with the two doses evaluated. We believe the taste profile is an important and potentially differentiating attribute for a nasal antihistamine spray."

The Phase 2 clinical trial was a 14-day, randomized, double-blind comparison of two doses of epinastine nasal spray (0.05% and 0.1%) to placebo in 569 subjects who had a documented history of seasonal allergic rhinitis to mountain cedar pollen. Of the subjects randomized in the trial, 95% completed the trial and no serious adverse events were reported. While the most common adverse event observed was bitter taste, it was only reported by 4% of subjects in the 0.05% group and by 5% of subjects in the 0.1% group.

The primary endpoint of the trial was the daily reflective change from baseline for total nasal symptom score (TNSS), averaged over the 14-day treatment period. The endpoint of TNSS conforms to the U.S. Food and Drug Administration's (FDA) draft guidance document for seasonal allergic rhinitis and includes runny nose, nasal congestion, itchy nose and sneezing. Results of the trial demonstrated statistically significant improvement (p less than or equal to 0.05) in reflective TNSS for the 0.1% dose group, compared to placebo. Changes in TNSS for the
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Presentations at Two European Scientific Conferences
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:10/19/2014)... 20, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its third quarter 2014 financial results on Wednesday, October ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Wednesday, October ...
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... CRT-Fallstudien gefragt. Das Problem dabei ist, ... Informationen mit der Kompetenz zu teilen. ... und deshalb freuen wir uns umso mehr, dass ... gebeten, ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit ...
(Date:10/17/2014)... , Oct. 17, 2014 With the ... Affairs function has come across several challenges in ... and managing globalization.  The ... is dedicated to providing benchmarking and best practices ... Consortium is a service composed of three stages: ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... DUBLIN , April 27, 2010 , ... EMOP Returns in May to Campione, Italy ; Sell Out Event Expected , ... European Masters of Poker returns for its fourth main event stop of,season two from May 28 to 30 ... Qualification for the EUR1,000 ...
... MADISON, Wis. , April 27 MCNC is ... pilot partnership with Sonic Foundry, Inc. (Nasdaq: ... and knowledge management. As part of its 25th anniversary celebration, ... of North Carolina by adding Mediasite ...
Cached Medicine Technology:European Masters of Poker Italy Online Qualification in Full Swing 2European Masters of Poker Italy Online Qualification in Full Swing 3MCNC Partners With Sonic Foundry to Provide Classroom Technology to K-20 Community 2MCNC Partners With Sonic Foundry to Provide Classroom Technology to K-20 Community 3MCNC Partners With Sonic Foundry to Provide Classroom Technology to K-20 Community 4
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is ... repair a damaged mitral valve as the heart continues ... by Abbott Vascular , is designed to treat ... in which the heart’s mitral valve leaflets fail to ... heart’s left ventricle into the left atrium. The heart ...
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 ... joined Specialists in Obstetrics & Gynecology of Columbus, Inc., ... specialized women’s healthcare services to more than 100,000 patients ... care though all ages and stages of a women’s ... office locations in Westerville and Dublin. , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Zereana Jess-Huff, a ... Mrs. Maryland 2014 on a platform to think outside the ... and uses her position to raise awareness about women’s other ... for breast cancer. You say the color pink and everybody ... know for a fact that it has not been won ...
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Rockynol ... Living Center on Oct. 14. The $11 million project ... services, and a cooked-to-order kitchen with full-service restaurant style ... premier choice for first class Assisted Living apartments,” said ... residents deserve the highest quality of care and this ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... , MONDAY, Aug. 16 (HealthDay News) -- The ... poses a health threat to clean-up workers, fishermen and members ... have examined the area. "Clinicians should be aware of, ... and related chemicals. Symptomatic patients should be asked about occupation ...
... first study to compare the effectiveness of the birth ... found that the pill works equally well in women ... physician-scientists at NewYork-Presbyterian Hospital/Columbia University Medical Center refutes a ... not reliably prevent pregnancy in women who are overweight ...
... , HOUSTON - A protein associated with cancer progression ... creation of new blood vessels that feed the tumor ... University of Texas MD Anderson Cancer Center reports in ... using a nanoparticle-based gene-silencing system to block production of ...
... most beautiful thing about humans, says Indiana University researcher S. ... prone to error. Yet humans are still extremely flexible and ... seamlessly. His new study demonstrates how this adaptability boils down ... ,God does not play dice., Unfortunately, we all have to ...
... asthma on the list of potential health risks posed ... uncovered. Furthermore, the practice of using ozone to remove ... hotel rooms and the interiors of vehicles, is probably ... researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) ...
... , MONDAY, Aug. 16 (HealthDay News) -- A new study finds ... much lower than what their wife or female partner makes, while ... than their husband or male partner. The findings suggest that ... among the young couples they studied. "With women, they were ...
Cached Medicine News:Health News:Gulf Oil Spill Still a Health Threat to Many, Researchers Report 2Health News:Gulf Oil Spill Still a Health Threat to Many, Researchers Report 3Health News:Birth control pill equally effective for women regardless of their weight 2Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 2Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 3Health News:Input-output trade-offs found in human information processing 2Health News:Berkeley study shows ozone and nicotine a bad combination for asthma 2Health News:Berkeley study shows ozone and nicotine a bad combination for asthma 3Health News:Infidelity Rises When She Makes More Than He Does 2Health News:Infidelity Rises When She Makes More Than He Does 3
... Mediware product, which serves as an ... a dynamic and complete representation of ... orders, medication list, allergies, and notes ... that increase patient safety. MediMAR uses ...
... to medication administration, any error is one ... solution is the Dynamic Hospital AdministratOR. This ... administration system, suitable for hospitals of all ... networked, or as a fully-integrated component of ...
... Outlook® Safety Infusion System is designed to ... drug, and the right dose. Available in ... Outlook® Safety Infusion System allows hospitals to ... meet their needs. DoseGuard™ dose limit technology ...
... that support the nursing process. The caregiver ... I&O information at the point of collection ... This design supports compliance with documentation requirements., ... at the nursing station, wCareAssist™ is right ...
Medicine Products: